The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …

Advances in artificial intelligence-based methods have led to the development and
publication of numerous systems for auto-segmentation in radiotherapy. These systems …

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the
nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these …

PURPOSE The aim of this joint guideline is to provide evidence-based recommendations to
practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy …

Nasopharyngeal carcinoma (NPC) is a disease with unique epidemiological features. The
distribution of the disease demonstrates a clear regional, racial and gender prevalence. In …

Simple Summary Nasopharyngeal carcinoma (NPC) is commonly treated using high-dose
radiotherapy. Careful radiotherapy planning is crucial for the eradication of cancer cells …

Arc proton therapy (ArcPT) is an emerging modality in cancer treatments. It delivers the
proton beams following a sequence of irradiation angles while the gantry is continuously …

Background The Danish Head and Neck Cancer Group (DAHANCA) was founded in 1976.
Over the years the group successfully conducted clinical trials and has developed national …

Nasopharyngeal carcinoma (NPC) is a squamous carcinoma with apparent geographical
and racial distribution, mostly prevalent in East and Southeast Asia, particularly …

Background Anti-PD-1 therapy and chemotherapy is a recommended first-line treatment for
recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains …